No benefit from presurgery aromatase inhibitor for HR-positive, HER2-positive breast cancer

December 9, 2016, American Association for Cancer Research

Adding an aromatase inhibitor to presurgery treatment with docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (Perjeta) did not significantly increase or decrease the percentage of patients with hormone receptor (HR)-positive, HER2-positive breast cancer who had a pathologic complete response (pCR), according to data from a phase III clinical trial presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6–10.

"Many with HR-positive, HER2-positive breast cancer who have large, operable breast tumors or evidence that the cancer has spread to underarm receive , carboplatin, trastuzumab, and pertuzumab before surgery, a treatment approach called neoadjuvant chemotherapy," said Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center, part of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston. "However, many of them don't respond optimally, especially if their tumors are also HR-positive. Preclinical and clinical data led us to test whether adding an aromatase inhibitor to this neoadjuvant treatment regimen in this patient group would increase the percentage of patients who have a pCR, meaning that they have no residual invasive cancer detectable in breast tissue and lymph nodes removed during surgery."

Among 308 patients who were randomly assigned docetaxel, carboplatin, trastuzumab, pertuzumab, and an aromatase inhibitor, 71 had a pCR (46.1 percent). Sixty three of the 154 patients who were randomly assigned docetaxel, carboplatin, trastuzumab, pertuzumab, and no aromatase inhibitor had a pCR (40.9 percent).

"We saw a modest numerical increase in the number of patients who had a pCR in the aromatase inhibitor arm of the study, but the increase was not statistically significant. There had been concern that chemotherapy and endocrine therapy may have opposing (antagonistic) effects. We did not see that," said Rimawi. "At this point, we cannot recommend a change to the standard-of-care neoadjuvant treatment regimen for patients with HR-positive, HER2-positive breast cancer but, the combination was safe and well tolerated. We are further analyzing tissue samples from the patients to investigate whether there are subgroups of patients who might benefit from the inclusion of an aromatase inhibitor in the neoadjuvant setting.

"Ultimately, we would like to de-escalate treatment for as many patients as it is safely possible to do so," continued Rimawi. "Discovering which patients need more therapy and which patients need less is crucial. Correlative studies from this and our other research efforts will provide critical information to move in that direction."

About 10 percent of breast cancer cases diagnosed in the United States are HR-positive, HER2-positive.

Rimawi and colleagues randomly assigned 315 patients with operable, locally advanced HR-positive, HER2-positive 1:1 to neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab treatment with or without an aromatase inhibitor. Premenopausal women randomly assigned aromatase inhibitor therapy also received ovarian function suppression with goserelin or an equivalent agent.

The proportion of patients who had grade 3 or grade 4 adverse events was similar among those whose neoadjuvant included an .

Explore further: Estrogen deprivation in neoadjuvant chemotherapy is not antagonistic to pathologic complete response

Related Stories

Estrogen deprivation in neoadjuvant chemotherapy is not antagonistic to pathologic complete response

December 9, 2016
Neoadjuvant chemotherapy in breast cancer treatment consists of administering docetaxel, carboplatin, trastuzumab and pertuzumab (TCHP) prior to surgery and is primarily used in patients with HER2-positive breast cancers ...

Presurgery abemaciclib treatment reduces cell proliferation in (HR)-positive, HER2-negative breast cancer

December 9, 2016
Presurgery treatment with the investigational therapeutic abemaciclib, either alone or in combination with the aromatase inhibitor anastrozole, reduced levels of Ki67, a marker of cell proliferation, in hormone receptor (HR)-positive, ...

Adding everolimus to fulvestrant improved outcomes for postmenopausal patients with HR-positive breast cancer

December 8, 2016
Progression-free survival was more than doubled for patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer resistant to aromatase inhibitor therapy by adding everolimus (Afinitor) to treatment ...

Adding Veliparib to chemotherapy improved response rates among patients with BRCA-mutant breast cancer

December 8, 2016
Adding the investigational poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate without increasing adverse events among patients who had locally ...

Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer

November 9, 2016
Neoadjuvant endocrine therapy - designed to reduce the size of breast tumors before surgical removal - appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast ...

Researchers to present event-free and overall survival results from NeoALTTO trial

December 11, 2013
Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented ...

Recommended for you

Scientists zero in on ways to boost colorectal cancer screening

October 17, 2018
A comprehensive analysis by University of North Carolina Lineberger Comprehensive Cancer Center researchers evaluated more than 70 clinical studies to identify some of the most effective methods for boosting U.S. colorectal ...

Gene screening technique helps identify genes involved in a fatty liver-associated liver cancer

October 17, 2018
With an estimated twenty-thousand protein-coding genes in the human genome, pinpointing a specific gene or pathway responsible for a particular disease can be like finding a needle in the proverbial haystack. This has certainly ...

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.